肿瘤坏死因子拮抗剂在原发性硬化性胆管炎患者中的效果
该回顾性分析纳入141例原发性硬化性胆管炎(PSC)合并炎症性肠病(IBD)患者,接受抗TNF药物治疗后IBD应答率48%、缓解率23%,PSC症状频率无变化;阿达木单抗组3个月ALP中位下降15%,英夫利西单抗组仅4%。
要点
- 抗TNF药物治疗PSC合并IBD患者IBD应答率48%、缓解率23%。
- 抗TNF治疗前后PSC症状频率无差异,未加重PSC症状。
- 阿达木单抗组3个月ALP中位下降15%,显著大于英夫利西单抗组4%。
核心结论
- 抗TNF药物对PSC合并IBD患者IBD疗效中等,未加重PSC症状或出现特定副作用。
- 阿达木单抗与ALP降低的关联需前瞻性研究进一步验证。
研究设计与样本
- 回顾性分析,纳入欧洲和北美20个中心(多为三级医疗中心)141例PSC合并IBD接受英夫利西单抗或阿达木单抗治疗的患者。
- 收集血清碱性磷酸酶(ALP)水平,IBD应答定义为内镜应答或(无内镜数据时)临床应答,缓解定义为内镜下黏膜愈合。
- 采用线性回归分析识别抗TNF治疗期间与ALP水平显著相关的因素。
主要发现
- 抗TNF治疗使48%患者IBD应答、23%患者IBD缓解。
- 抗TNF暴露前后PSC症状频率无差异。
- 停用抗TNF最常见原因为IBD原发无应答(17%)和副作用(18%)。
临床怎么用
- 抗TNF药物可用于PSC合并IBD患者,IBD应答率中等且不加重PSC症状。
- 选择阿达木单抗可能更有利于降低ALP,但证据尚需前瞻性研究确认。
局限性
- 回顾性分析设计。
- 样本量141例,多来自三级医疗中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. METHODS: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. RESULTS: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P = .035). Factors associated with lower ALP were normal ALP at baseline (P < .01), treatment with adalimumab (P = .090), and treatment in Europe (P = .083). CONCLUSIONS: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.
引用
- Hedin CRH, Sado G, Ndegwa N, et al. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2020. PMID: 32068151. doi:10.1016/j.cgh.2020.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。